Menu Close

CDC phone consultation for fungal meningitis cases

Premier Communications

SafetyShare® newsletter brought to you by the Premier Safety Institute ®
Gina Pugliese, RN, MS, editor


CDC launches clinician telephone consultation for fungal meningitis cases

CDC launches clinician telephone consultation for fungal meningitis cases

CDC has just launched a new email and telephone-based Clinicians Consultation Network service to assist clinicians treating
patients who received injections with the contaminated steroid medication.

In addition, CDC is alerting clinicians of two unusual clinical complications – epidural abscess and arachnoiditis – among a
portion of patients undergoing treatment for meningitis associated with injections of a contaminated steroid medication, preservative-free
methylprednisolone acetate.

Clinicians Consultation Network

Beginning on November 6, CDC is establishing a volunteer Clinicians Consultation Network of experts in fungal disease treatment and management to assist
physicians who are directly involved in the treatment of patients associated with the current outbreak of fungal meningitis and other infections. Through
this service, doctors who are treating patients will be able to consult by telephone or email with one of a group of participating infectious disease
medical experts. To access the service, physicians should call 1-800-CDC-INFO (1-800-232-4636) and then select
the appropriate prompts (e.g., “1” for English, “1” for Clinician). A CDC-INFO call agent will verify each physician’s role in direct patient management.
After this verification, the calling physician will be referred to the Clinicians Consultation Network. The Network consultants have entered into volunteer
agreements with CDC to provide this consultation service to treating physicians. There is no charge for the consultation. The consultants will report their
findings to CDC, which may provide valuable information for the response to the outbreak. Operating hours for the service are the same as those for
CDC-INFO: 8:00 am to 8:00 pm Monday through Friday (Eastern Time), except federal holidays.

If you have questions about the Clinicians Consultation Network, please contact CDC-INFO (1-800-232-4636).

New Information on Clinical Course

During the course of this investigation, CDC has worked closely with a group of fungal infectious disease experts who provided their individual input to
help CDC develop interim guidance and other information about clinical aspects of the outbreak, including patient management and treatment. The guidance
documents have been updated regularly as CDC and its partners have learned more about the outbreak; the latest versions are available on CDC’s
outbreak-related Clinician Guidance webpage at CDC has also advised that
healthcare providers involved in the treatment of these patients consult with an infectious disease medical specialist because of the diagnostic and
clinical challenges presented by these fungal infections.

CDC has recently become aware of reports of epidural abscess and arachnoiditis among a number of patients undergoing treatment for fungal meningitis
associated with injections of contaminated steroid. Spinal epidural abscesses are characterized by inflammation and a collection of pus around the spine,
sometimes resulting in swelling of the infected areas (though several recently reported patients with this condition had no detectable swelling).
Arachnoiditis is caused by inflammation of the arachnoid, one of the membranes that surround and protect the nerves of the spinal cord. Both conditions are
normally rare but serious disorders that require prompt medical attention. Most of these early reports have been for patients in Michigan and Tennessee,
but other states have reported patients with these conditions as well. CDC is working with clinicians and public health officials to obtain more
information and refine its clinical guidance as needed.

For additional information about the outbreak of fungal meningitis and other infections, see CDC’s website at


Safety Institute




Topics  – 
Unsubscribe  –

Editorial team

You may forward this newsletter to your colleagues.

If you would like to reprint any of these stories,

please cite the “SafetyShare newsletter, Premier Inc.” as your source
and send an email to
and alert us. Thank you.